-
International Journal of Nephrology and Renovascular Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment
Review
(3979) Views (2022) Full article downloads
Authors: Christian R Halvorson, Matthew S Bremmer, Stephen C Jacobs
Published Date June 2010
Volume 2010:3 Pages 69 - 83
DOI: http://dx.doi.org/10.2147/IJNRD.S6939
Christian R Halvorson1, Matthew S Bremmer1, Stephen C Jacobs1
1Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA
Abstract: Both autosomal dominant and recessive polycystic kidney disease are conditions with severe associated morbidity and mortality. Recent advances in the understanding of the genetic and molecular pathogenesis of both ADPKD and ARPKD have resulted in new, targeted therapies designed to disrupt cell signaling pathways responsible for the abnormal cell proliferation, dedifferentiation, apoptosis, and fluid secretion characteristic of the disease. Herein we review the current understanding of the pathophysiology of these conditions, as well as the current treatments derived from our understanding of the mechanisms of these diseases.
Keywords: Polycystic kidney disease, autosomal dominant, recessive, end stage renal disease
Readers of this article also read:
The use of everolimus in renal-transplant patients
Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin
Nephrolithiasis-induced end stage renal disease
Health literacy and health seeking behavior among older men in a middle-income nation
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Update on the diagnosis and management of acute kidney injury
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Emerging drug combinations to optimize renovascular protection and blood pressure goals
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Potential renovascular hypertension, space missions, and the role of magnesium
- The use of everolimus in renal-transplant patients
- Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate




